{ "schema_version": "uw.editorial_geo.v1", "representation_profile": "lossless_source_sections", "local_stage_only": true, "catalog_id": "DEP-06-N06", "article_index": "DEP-06-N06", "language": "en", "headline": "Sleeping medicines and Z-drugs", "description": "Sleeping medicines and Z-drugs", "short_answer": "For someone who has struggled to fall asleep for a long time, a medicine's benefit can be very noticeable: a night of rest, easier work and easier conversations with loved ones. That benefit need not be dismissed as an illusion. But sleep, alertness the following day, physical adaptation to a medicine and freedom to manage its use are different questions. One successful outcome cannot answer all the others.\n\nA hypothetical remark: “I finally sleep, but I fear I cannot manage without the tablet now.” It may express fear of the old insomnia, symptoms after treatment changes, unwanted effects or lost confidence. Fear itself does not establish addiction. A long-standing prescription also cannot automatically establish its presence or absence.\n\nSuspected poisoning, unconsciousness or difficulty breathing require immediate local emergency medical help. Do not wait for a routine review, a complete list of products or a prepared note. [NHS, poisoning](https://www.nhs.uk/conditions/poisoning/).", "short_answer_source": { "kind": "first_introductory_h2_after_h1", "role": "lead", "start_utf16": 93, "end_utf16": 1093, "sha256_utf8": "58760ecb75ee9ce67c0e86d5ebd3ed8b63e34b6762f44cb93832cf8d6d0f09ee" }, "headline_source": { "role": "h1_heading", "start_utf16": 2, "end_utf16": 32, "sha256_utf8": "ee65d05e581fecf99c4793e6cc69387f5b97bda7be0edc0eafd682149f9226d7" }, "entities": [], "questions": [ { "q": "Sleep, relief and questions about continuing treatment", "a": "For someone who has struggled to fall asleep for a long time, a medicine's benefit can be very noticeable: a night of rest, easier work and easier conversations with loved ones. That benefit need not be dismissed as an illusion. But sleep, alertness the following day, physical adaptation to a medicine and freedom to manage its use are different questions. One successful outcome cannot answer all the others.\n\nA hypothetical remark: “I finally sleep, but I fear I cannot manage without the tablet now.” It may express fear of the old insomnia, symptoms after treatment changes, unwanted effects or lost confidence. Fear itself does not establish addiction. A long-standing prescription also cannot automatically establish its presence or absence.\n\nSuspected poisoning, unconsciousness or difficulty breathing require immediate local emergency medical help. Do not wait for a routine review, a complete list of products or a prepared note. [NHS, poisoning](https://www.nhs.uk/conditions/poisoning/).", "source_spans": [ { "role": "h2_heading", "start_utf16": 37, "end_utf16": 91, "sha256_utf8": "36cf6f754428b50bdf11e651c3742d906687a7dbd0cc346e4cb78e0a1f194d50" }, { "role": "h2_answer", "start_utf16": 93, "end_utf16": 1093, "sha256_utf8": "58760ecb75ee9ce67c0e86d5ebd3ed8b63e34b6762f44cb93832cf8d6d0f09ee" } ], "block_ids": [ "p0003", "p0004", "p0005" ], "source_segment_index": 1 }, { "q": "What is called a sleeping medicine?", "a": "The term “sleeping medicine” describes a purpose rather than one uniform class. NHLBI lists several medicine groups for insomnia, as well as products prescribed on other grounds. Their indications, risks and intended durations differ. A general name therefore cannot replace the particular product's name and prescribing information. [NHLBI, insomnia treatment](https://www.nhlbi.nih.gov/health/insomnia/treatment).\n\nIn its US explanation, FDA identifies zolpidem, zaleplon and eszopiclone as examples of Z-drugs. They may help with sleep problems, but that does not mean serious risks are absent. The letter Z is not a sign of a “safe new generation,” and approval abroad does not establish local legality or availability for any product. [FDA, Z-drugs](https://www.fda.gov/consumers/consumer-updates/taking-z-drugs-insomnia-know-risks).\n\nOver-the-counter products and supplements do not become risk-free substitutes simply because of where they are sold. Discuss everything already being taken, including prescribed medicines and other substance use. This article selects no product and provides no compatibility chart.", "source_spans": [ { "role": "h2_heading", "start_utf16": 1098, "end_utf16": 1133, "sha256_utf8": "ed767dad48bbdf450cc75a07f996891cf399c316fbfc3eff53f84aa1ae6a3296" }, { "role": "h2_answer", "start_utf16": 1135, "end_utf16": 2256, "sha256_utf8": "4d4c90af058a468b84f9d511f70ce122eab73d9fbc80e7b1290a395bd80e0c02" } ], "block_ids": [ "p0007", "p0008", "p0009" ], "source_segment_index": 2 }, { "q": "Why an extended prescription deserves review", "a": "Better sleep answers an important question but does not finish the discussion of treatment. What remains difficult during the day? Has the benefit changed? What unwanted effects have appeared? Does the prescriber know about other products and living circumstances? A review can clarify the next task without denying relief already received.\n\nThe US prescribing information for the particular zolpidem product AMBIEN specifies short-term use for difficulty initiating sleep; long-term use is not recommended, and an extension requires reassessment. This is the limit of that named label, rather than one stopping deadline for every sleeping medicine or a conclusion that every long-term patient has a disorder. [AMBIEN, DailyMed label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c36cadf4-65a4-4466-b409-c82020b42452).\n\nIn January 2026, the UK's MHRA announced strengthened warnings about dependence, withdrawal and tolerance for several classes, including Z-drugs. This was a particular regulatory review of risk communication, rather than a study of every prescription's effectiveness. Packaging updates were described as an ongoing process, rather than an already completed worldwide change. [MHRA, warnings and scope](https://www.gov.uk/drug-safety-update/improving-information-supplied-with-gabapentinoids-pregabalin-slash-gabapentin-benzodiazepines-and-z-drugs).", "source_spans": [ { "role": "h2_heading", "start_utf16": 2261, "end_utf16": 2305, "sha256_utf8": "628c3b66e7179e4090bf3fe2b2b9f481f26a1553770c62d56a76fff822ec6121" }, { "role": "h2_answer", "start_utf16": 2307, "end_utf16": 3687, "sha256_utf8": "537edcb657414d1683762c97dda3a06b2c86349a020b107f73e35272d93495e9" } ], "block_ids": [ "p0011", "p0012", "p0013" ], "source_segment_index": 3 }, { "q": "Adaptation, tolerance and addiction differ", "a": "Physical dependence means adaptation to a substance's presence; reducing or stopping use may be accompanied by withdrawal symptoms. Tolerance may appear as previous relief feeling weaker. Addiction involves problematic use, a desire to take the substance and difficulties with control. MHRA explicitly explains that physical dependence does not necessarily mean addiction. These descriptions do not become a home diagnostic test. [MHRA, distinctions](https://www.gov.uk/drug-safety-update/improving-information-supplied-with-gabapentinoids-pregabalin-slash-gabapentin-benzodiazepines-and-z-drugs).\n\nIf someone feels their medicine helps less, they can tell a professional. This is not an instruction to increase the amount, add another sleeping medicine or test control by skipping it. Continuing to work does not exclude risk simply because someone is still managing their tasks.\n\nFor zolpidem, the label describes symptoms after rapid reduction or abrupt discontinuation, including possible severe manifestations. Seizures or marked confusion require immediate local emergency medical help. This is not a forecast for everyone, a withdrawal calendar or a rule to test for symptoms yourself. Difficulties stopping are discussed with the prescribing professional. [AMBIEN, dependence and withdrawal](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c36cadf4-65a4-4466-b409-c82020b42452).", "source_spans": [ { "role": "h2_heading", "start_utf16": 3692, "end_utf16": 3734, "sha256_utf8": "12e3a3bc371206d3375779a0e3d5ef3fdb9e9e7d40f325d564afe37e20809849" }, { "role": "h2_answer", "start_utf16": 3736, "end_utf16": 5131, "sha256_utf8": "1f33e73521d3d23ddbed7177c248cba83c63d888fab385955b89450b64255651" } ], "block_ids": [ "p0015", "p0016", "p0017" ], "source_segment_index": 4 }, { "q": "A poor night does not establish the cause", "a": "Sleep problems may have preceded the medicine. After a treatment change, previous insomnia, withdrawal symptoms, unwanted effects, anxiety and other circumstances can overlap. One number of hours slept or one unpleasant episode cannot reliably identify the cause.\n\nNHLBI describes assessing sleep history, daytime condition, illnesses, medicines and use of other substances. A clinician may also consider other sleep disorders, such as sleep apnoea. This does not require readers to order their own investigations or watch another person's breathing all night. Describe what is already known and mark what remains unknown. [NHLBI, insomnia assessment](https://www.nhlbi.nih.gov/health/insomnia/diagnosis).\n\nYou do not have to spend a night without medicine to prove “real insomnia,” or repeat a dangerous episode to test it. Uncertainty can be part of seeking help. Insufficient sleep does not demonstrate a weak mind, and access to help does not depend on revealing supposed hidden trauma or completely changing your surroundings.", "source_spans": [ { "role": "h2_heading", "start_utf16": 5136, "end_utf16": 5177, "sha256_utf8": "a2b9b22384e1786144aa084e54f9cc76b0ccc44120a67e3abcb8a20e999b7174" }, { "role": "h2_answer", "start_utf16": 5179, "end_utf16": 6210, "sha256_utf8": "caa144ef3ae7b864bceb0fc0eab4762dfd1b7f35721a5fb90176843b304f22c9" } ], "block_ids": [ "p0019", "p0020", "p0021" ], "source_segment_index": 5 }, { "q": "Caution matters after a night's sleep too", "a": "FDA warns about next-day drowsiness and impaired ability to perform activities requiring attention. Feeling that you slept or completed work does not replace assessment of those risks. Daytime condition, errors and safety matter in the discussion, rather than falling asleep alone. [FDA, daytime effects](https://www.fda.gov/consumers/consumer-updates/taking-z-drugs-insomnia-know-risks).\n\nA separate risk involves activities while not fully awake, such as walking or driving, which the person may not remember later. Such episodes have been described for the named Z-drugs and can cause serious harm. If an episode has already happened, contact a medical professional immediately for an urgent decision about further care and medicine use; do not postpone this until a routine visit. Immediate danger requires emergency help. This is not an ordinary question about planned discontinuation or a reason to repeat use to test memory.\n\nCombinations with alcohol, other sleeping medicines or opioids need separate assessment; the zolpidem label warns about increased central nervous system depression and breathing risk. Reporting combinations already taken is more useful than trying to find a “compatible” combination yourself. [AMBIEN, warnings](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c36cadf4-65a4-4466-b409-c82020b42452).", "source_spans": [ { "role": "h2_heading", "start_utf16": 6215, "end_utf16": 6256, "sha256_utf8": "c203c8bef6b3697a374e2ef6dfaf0d3197704fa5704506600fbb9bfc47c00671" }, { "role": "h2_answer", "start_utf16": 6258, "end_utf16": 7598, "sha256_utf8": "70819fbc0a9e779e1a1af64044703efb37875803996631fd4adf7cacc29af1f3" } ], "block_ids": [ "p0023", "p0024", "p0025" ], "source_segment_index": 6 }, { "q": "Treating insomnia involves more than “pull yourself together”", "a": "Cognitive behavioural therapy for insomnia, CBT-I, is a distinct, multicomponent approach. AASM's 2021 guideline recommends it for adults with chronic insomnia; sleep-hygiene advice alone is not recommended as the sole treatment. This is a clinical recommendation within the stated scope, rather than a promise that everyone will recover or must first follow a perfect routine. [AASM, guideline](https://pubmed.ncbi.nlm.nih.gov/33164742/).\n\nNHLBI also describes CBT-I as an option for professional care for long-term insomnia. It can be discussed alongside medicines, the person's condition and access. This article does not reproduce sleep-restriction exercises, time-in-bed schedules or a self-directed course. You need not experiment with sleep deprivation or stop a prescription yourself to begin discussing another approach. [NHLBI, treatment options](https://www.nhlbi.nih.gov/health/insomnia/treatment).\n\nIf qualified care is unavailable or too expensive, that is a real barrier rather than inadequate effort. A starting point can be the prescriber, a pharmacist to clarify product information, or an accessible medical service. Ask who can assess continuing treatment, about cost and language, and what help is available while waiting. Booking an appointment is a first contact, rather than completed treatment. [SAMHSA, seeking care](https://www.samhsa.gov/find-support/health-care-or-support/how-to-set-up-an-appointment).", "source_spans": [ { "role": "h2_heading", "start_utf16": 7603, "end_utf16": 7664, "sha256_utf8": "c8118bb46164335ac7203835bdd565fff92e8d4b43ded778fa3a3beed05dcf15" }, { "role": "h2_answer", "start_utf16": 7666, "end_utf16": 9098, "sha256_utf8": "82131e53c2c6b65d3d3d83d5b9b2689c9676eef3e15ef97b2fb7cdda800762a8" } ], "block_ids": [ "p0027", "p0028", "p0029" ], "source_segment_index": 7 }, { "q": "Support from relatives and five optional fields", "a": "A relative can offer help with a contact or report events already noticed, with the adult's consent. They need not become solely responsible for sleep and treatment, control the medicine or watch the person all night. A child must not be made a monitor of an adult's sleep, breathing or mood. When threats or violence occur, protecting those harmed matters in its own right. A relative's own support and rest matter too. [SAMHSA, caring for yourself while supporting someone](https://www.samhsa.gov/find-support/helping-someone/caring-for-yourself).\n\nFor an ordinary consultation, prepare only information already known. This is not a diagnostic scale, a diary with a mandatory duration or a condition for getting help; any field can be left blank. Notes are unnecessary during immediate danger.\n\n1. **Medicine and purpose.** What treatment was prescribed and why, as far as I know; name other substance use separately.\n2. **Night-time benefit and daytime condition.** What changed in sleep and everyday activities, what matters to preserve and what concerns me.\n3. **Changes that have already happened.** What happened with the prescription and how I felt; do not declare unknown causes established.\n4. **Events and questions.** What unwanted effects or dangerous episodes are already known, and what needs urgent discussion. Do not create a new episode for the note.\n5. **Next contact and support.** Whom I can approach, what prevents access and what manageable help from an adult can be agreed.", "source_spans": [ { "role": "h2_heading", "start_utf16": 9103, "end_utf16": 9150, "sha256_utf8": "811b14bf338e2a81120abfa57a6abc784736b9a85c0feba67da73af21c6f7c7e" }, { "role": "h2_answer", "start_utf16": 9152, "end_utf16": 10649, "sha256_utf8": "807d0041b138ddd47d5624d819e39f8eeff9531275044b5ecc78e5e9a13c120f" } ], "block_ids": [ "p0031", "p0032", "p0033" ], "source_segment_index": 8 }, { "q": "Sources and limits", "a": "Sources were checked on 14 October 2026 within the specified scopes. No individual prescription, diagnosis, safety guarantee or local availability is established. Revision, record-update and retrieval dates differ; US and UK sources do not establish legal status in Russia or Thailand.\n\n- [MHRA, Improving Information Supplied with Gabapentinoids, Benzodiazepines and Z-Drugs](https://www.gov.uk/drug-safety-update/improving-information-supplied-with-gabapentinoids-pregabalin-slash-gabapentin-benzodiazepines-and-z-drugs) — 8 January 2026; the main communication on warnings and conceptual distinctions was read. The review did not assess all products' efficacy; epilepsy and procedural sedation were outside its scope. The footer states OGLv3 with exceptions; the linked licence returned403 and is not claimed as read.\n- [FDA, Taking Z-drugs for Insomnia? Know the Risks](https://www.fda.gov/consumers/consumer-updates/taking-z-drugs-insomnia-know-risks) — the main patient communication was read; a substantive revision date was not established in the displayed text. Named medicines, benefit and particular risks, rather than all studies or worldwide approval.\n- [AMBIEN, DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c36cadf4-65a4-4466-b409-c82020b42452) — record updated15April2025; archive version26 published18April2025; label text Revised2/2022. Selected indications, warnings and dependence/withdrawal sections were read. Not the full1155-line document, all trials or administration instructions. A general full-text licence was not established.\n- [NHLBI, Insomnia Diagnosis](https://www.nhlbi.nih.gov/health/insomnia/diagnosis) — 24 March 2022; history assessment, other possible problems and the date were read. Diagnostic thresholds, studies and diary forms were not transferred.\n- [NHLBI, Insomnia Treatment](https://www.nhlbi.nih.gov/health/insomnia/treatment) — 24 March 2022; CBT-I, differences between approaches and medicine information were read. Not all linked studies or a self-directed sleep-restriction programme.\n- [Edinger et al., AASM guideline](https://pubmed.ncbi.nlm.nih.gov/33164742/) — J Clin Sleep Med2021,17(2):255–262; DOI10.5664/jcsm.8986. The entire displayed official abstract and metadata were read, rather than the full paper, evidence reviews or underlying trials. General full-text rights were not established; a short original attributed summary is provided.\n- [NHS, Poisoning](https://www.nhs.uk/conditions/poisoning/) — 12 June 2025; verified reuse of the author's own reading on urgent care, without UK telephone numbers or home procedures.\n- [SAMHSA, How to Set Up an Appointment](https://www.samhsa.gov/find-support/health-care-or-support/how-to-set-up-an-appointment) — 24 April 2023; verified reuse of the author's own reading of the entire displayed official expanded text, direct HTML403; first-contact questions rather than guaranteed services.\n- [SAMHSA, Caring for Yourself](https://www.samhsa.gov/find-support/helping-someone/caring-for-yourself) — 24 April 2023; verified reuse of the author's own reading of the entire displayed official expanded text, direct opening InternalError; manageable support rather than treatment delivered by a relative.", "source_spans": [ { "role": "h2_heading", "start_utf16": 10654, "end_utf16": 10672, "sha256_utf8": "f91f16500d95114ea5dd62762b302ab95f247ca4f49fe0affb04993b09f0a299" }, { "role": "h2_answer", "start_utf16": 10674, "end_utf16": 13901, "sha256_utf8": "42f16131643d57b80b8c88208033349aae70a5e332d8bca308024512eebabed3" } ], "block_ids": [ "p0035", "p0036" ], "source_segment_index": 9 }, { "q": "Tags", "a": "sleeping medicines; Z-drugs; insomnia; treatment benefit; long-term use; physical adaptation; tolerance; withdrawal symptoms; daytime drowsiness; CBT-I; prescription review; support for relatives", "source_spans": [ { "role": "h2_heading", "start_utf16": 13906, "end_utf16": 13910, "sha256_utf8": "1331275bc537b4c2bf1e46f7275677967515342e30b572e6852fa6f51b831fe8" }, { "role": "h2_answer", "start_utf16": 13912, "end_utf16": 14107, "sha256_utf8": "904b41d50bf6f021ec5394679139fa1cd6f02c5e63848e4a3e3aa0309cf19fde" } ], "block_ids": [ "p0038" ], "source_segment_index": 10 }, { "q": "About the authors", "a": "Andrey Zarinsh is the author and founder of United Wisdom. He explores inner transformation, the unity of traditions, intercultural dialogue and contemporary spiritual discipline. Instagram: @andrey.zarinsh.\n\nMaria Evilkut is a co-author of United Wisdom. Alongside her research, she seeks to test these ideas in practice and observe how principles of unity and mutual understanding work in real life between people and cultures. Instagram: @ilkutki.", "source_spans": [ { "role": "h2_heading", "start_utf16": 14112, "end_utf16": 14129, "sha256_utf8": "e120452a2b9952200310f55df00e52d0bbd068d32bba8a322511ed65e3d4967d" }, { "role": "h2_answer", "start_utf16": 14131, "end_utf16": 14581, "sha256_utf8": "b807861bc19a25ab91f45e5acc6d733c04ea03b84b346d9e77c2381c9e3498ed" } ], "block_ids": [ "p0040", "p0041" ], "source_segment_index": 11 } ], "claims": [], "claims_policy": "no_reclassified_claims", "sources": [ { "id": "src_10790fb1fab48f9a", "title": "NHS, Poisoning", "url": "https://www.nhs.uk/conditions/poisoning/", "source_spans": [ { "role": "markdown_link", "start_utf16": 1034, "end_utf16": 1092, "sha256_utf8": "4df8a92091531b6a767c67412d798b2ba441449a7c75ce3f1df2da2181151083" }, { "role": "markdown_link", "start_utf16": 13099, "end_utf16": 13157, "sha256_utf8": "c856a80773ac625d62d1ae76d38ae84591b6453e27268e52b90c33b8d6c136bc" } ], "read_scope": "- [NHS, Poisoning](https://www.nhs.uk/conditions/poisoning/) — 12 June 2025; verified reuse of the author's own reading on urgent care, without UK telephone numbers or home procedures.", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 13097, "end_utf16": 13281, "sha256_utf8": "a5a174cdab7edbef910b4fa8e9a7d7ca7ba77a074bd7615df678a40e46288eee" }, "shared_entry_urls": [] }, { "id": "src_ef05d25603b2cbd8", "title": "NHLBI, Insomnia Treatment", "url": "https://www.nhlbi.nih.gov/health/insomnia/treatment", "source_spans": [ { "role": "markdown_link", "start_utf16": 1469, "end_utf16": 1549, "sha256_utf8": "2b8312ae69d3fc402d13c5c383a22986ca731ea274065442f412e80718e6d5b9" }, { "role": "markdown_link", "start_utf16": 8496, "end_utf16": 8575, "sha256_utf8": "711a39e123274a92a00e8dd41c992d02ec58fc17f9bd0227e6bef9e1616035a5" }, { "role": "markdown_link", "start_utf16": 12490, "end_utf16": 12570, "sha256_utf8": "41ae9e3698cb4d920cfd6ce88c2258f78c8411f1559e6021138fffd78e113582" } ], "read_scope": "- [NHLBI, Insomnia Treatment](https://www.nhlbi.nih.gov/health/insomnia/treatment) — 24 March 2022; CBT-I, differences between approaches and medicine information were read. Not all linked studies or a self-directed sleep-restriction programme.", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 12488, "end_utf16": 12732, "sha256_utf8": "6050251fde64bc73ef2220fc6941e5d4d1354f0bf55a26d45821a12d254ea653" }, "shared_entry_urls": [] }, { "id": "src_7524c206850e88c7", "title": "FDA, Taking Z-drugs for Insomnia? Know the Risks", "url": "https://www.fda.gov/consumers/consumer-updates/taking-z-drugs-insomnia-know-risks", "source_spans": [ { "role": "markdown_link", "start_utf16": 1875, "end_utf16": 1972, "sha256_utf8": "8a6567ab6e48f8c22bf182bee13c059cee63e4e18f4ac78b96ae344fbcde1da9" }, { "role": "markdown_link", "start_utf16": 6540, "end_utf16": 6645, "sha256_utf8": "c925884257391b550db3c72d8c9e4e570f0a49896396bfddac571239b0afaebe" }, { "role": "markdown_link", "start_utf16": 11497, "end_utf16": 11630, "sha256_utf8": "2f3277121809fc88a7df7302d0ba2b799d9c6349493df8912ad9593a06836d7a" } ], "read_scope": "- [FDA, Taking Z-drugs for Insomnia? Know the Risks](https://www.fda.gov/consumers/consumer-updates/taking-z-drugs-insomnia-know-risks) — the main patient communication was read; a substantive revision date was not established in the displayed text. Named medicines, benefit and particular risks, rather than all studies or worldwide approval.", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 11495, "end_utf16": 11838, "sha256_utf8": "49981d935f3b73a90d0cad141cc24e1762a8d7bcdfde33d7725ff286f28ad9ca" }, "shared_entry_urls": [] }, { "id": "src_519946aae1b59aca", "title": "AMBIEN, DailyMed", "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c36cadf4-65a4-4466-b409-c82020b42452", "source_spans": [ { "role": "markdown_link", "start_utf16": 3017, "end_utf16": 3136, "sha256_utf8": "b6bf2641a95b05e5a1c0e4fd66fb42e45385bd57cf904e88412da3d7c737b89a" }, { "role": "markdown_link", "start_utf16": 5000, "end_utf16": 5130, "sha256_utf8": "245fcfb24b344899d6406ef46451b74bdd736263b9b299c697c15a0b1703c00f" }, { "role": "markdown_link", "start_utf16": 7484, "end_utf16": 7597, "sha256_utf8": "b76b05fb1b5a49199e5e806cd64e0b59cb96e0cc7012aa9344fef5110f878ac5" }, { "role": "markdown_link", "start_utf16": 11841, "end_utf16": 11954, "sha256_utf8": "29872d4a8e344d91ca09be9636000beb7a38ce061470b0d3f6da426c8f5036fc" } ], "read_scope": "- [AMBIEN, DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c36cadf4-65a4-4466-b409-c82020b42452) — record updated15April2025; archive version26 published18April2025; label text Revised2/2022. Selected indications, warnings and dependence/withdrawal sections were read. Not the full1155-line document, all trials or administration instructions. A general full-text licence was not established.", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 11839, "end_utf16": 12250, "sha256_utf8": "6268ca613ec07bf92b9deb4590187d3e68f139a41e488e55f5d6cfc46ff6fd85" }, "shared_entry_urls": [] }, { "id": "src_0e3b8b7f299456c3", "title": "MHRA, Improving Information Supplied with Gabapentinoids, Benzodiazepines and Z-Drugs", "url": "https://www.gov.uk/drug-safety-update/improving-information-supplied-with-gabapentinoids-pregabalin-slash-gabapentin-benzodiazepines-and-z-drugs", "source_spans": [ { "role": "markdown_link", "start_utf16": 3514, "end_utf16": 3686, "sha256_utf8": "ff80f5301664cf5ac862dc9cd0f8c840c2d1611b58ce7ca87f8375556d6b5257" }, { "role": "markdown_link", "start_utf16": 4166, "end_utf16": 4332, "sha256_utf8": "7d29eca0ed0e1f22453b6bb80541104a55a4642d790deb6da8ef2dda4e9c05e1" }, { "role": "markdown_link", "start_utf16": 10963, "end_utf16": 11196, "sha256_utf8": "3507fa136f86a1ea0a3a898438b82539d6df1c20863193af9354e504f17722e2" } ], "read_scope": "- [MHRA, Improving Information Supplied with Gabapentinoids, Benzodiazepines and Z-Drugs](https://www.gov.uk/drug-safety-update/improving-information-supplied-with-gabapentinoids-pregabalin-slash-gabapentin-benzodiazepines-and-z-drugs) — 8 January 2026; the main communication on warnings and conceptual distinctions was read. The review did not assess all products' efficacy; epilepsy and procedural sedation were outside its scope. The footer states OGLv3 with exceptions; the linked licence returned403 and is not claimed as read.", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 10961, "end_utf16": 11494, "sha256_utf8": "8c259aa8f0278f0d6e78fdd4cc19a2523ee36d49aca70b6a11064c63619dc3d3" }, "shared_entry_urls": [] }, { "id": "src_d337bc5f51b979bf", "title": "NHLBI, Insomnia Diagnosis", "url": "https://www.nhlbi.nih.gov/health/insomnia/diagnosis", "source_spans": [ { "role": "markdown_link", "start_utf16": 5802, "end_utf16": 5883, "sha256_utf8": "f8f4eff5810f994430aaa995425d9b3a97088e59bbb6fc4a8ee5bf5cf7a0b387" }, { "role": "markdown_link", "start_utf16": 12253, "end_utf16": 12333, "sha256_utf8": "d04940b7f63610e8077716993371944ce5df9dcb8e0156544d24c1113c3de420" } ], "read_scope": "- [NHLBI, Insomnia Diagnosis](https://www.nhlbi.nih.gov/health/insomnia/diagnosis) — 24 March 2022; history assessment, other possible problems and the date were read. Diagnostic thresholds, studies and diary forms were not transferred.", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 12251, "end_utf16": 12487, "sha256_utf8": "94c704cfd3f71fa6ffd612803ac75727315f0bfab4f151832da62c5065aa4c20" }, "shared_entry_urls": [] }, { "id": "src_d5b17c639e2ce2ea", "title": "Edinger et al., AASM guideline", "url": "https://pubmed.ncbi.nlm.nih.gov/33164742/", "source_spans": [ { "role": "markdown_link", "start_utf16": 8044, "end_utf16": 8104, "sha256_utf8": "acd38601da25173ece47399c8f105ccad861e6fa29bbf4ba68c058c1ee63132e" }, { "role": "markdown_link", "start_utf16": 12735, "end_utf16": 12810, "sha256_utf8": "bebc52f564e08dc9a58fb5774c343b5d1e7574cbe0b2be5b43cc3a7dc85018e3" } ], "read_scope": "- [Edinger et al., AASM guideline](https://pubmed.ncbi.nlm.nih.gov/33164742/) — J Clin Sleep Med2021,17(2):255–262; DOI10.5664/jcsm.8986. The entire displayed official abstract and metadata were read, rather than the full paper, evidence reviews or underlying trials. General full-text rights were not established; a short original attributed summary is provided.", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 12733, "end_utf16": 13096, "sha256_utf8": "63d27457b2241112826b2c394672f658d371c5a2d6136586c9f9c2619c75567a" }, "shared_entry_urls": [] }, { "id": "src_96d8458a638ca14b", "title": "SAMHSA, How to Set Up an Appointment", "url": "https://www.samhsa.gov/find-support/health-care-or-support/how-to-set-up-an-appointment", "source_spans": [ { "role": "markdown_link", "start_utf16": 8986, "end_utf16": 9097, "sha256_utf8": "f608a7df7719acdb8599b215a27cd6a04dfd9b880ede7fe00dde217524d3cb43" }, { "role": "markdown_link", "start_utf16": 13284, "end_utf16": 13411, "sha256_utf8": "a74ebfa3d6bfe41b7bace4eec82e3ba2ccfbe77fda2a776c325b82072a93768e" } ], "read_scope": "- [SAMHSA, How to Set Up an Appointment](https://www.samhsa.gov/find-support/health-care-or-support/how-to-set-up-an-appointment) — 24 April 2023; verified reuse of the author's own reading of the entire displayed official expanded text, direct HTML403; first-contact questions rather than guaranteed services.", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 13282, "end_utf16": 13592, "sha256_utf8": "606398f838bf63ddcd6df30d948a6f2a1b24dcedf59fc113107bd91a119e689e" }, "shared_entry_urls": [] }, { "id": "src_c7cfed956c8066f2", "title": "SAMHSA, Caring for Yourself", "url": "https://www.samhsa.gov/find-support/helping-someone/caring-for-yourself", "source_spans": [ { "role": "markdown_link", "start_utf16": 9573, "end_utf16": 9700, "sha256_utf8": "44104394bc28e2b7e7aa3d384513437fd8d91c4c32f74c57393a36be19293f1c" }, { "role": "markdown_link", "start_utf16": 13595, "end_utf16": 13697, "sha256_utf8": "db10acdcd5a327dfe4ba5b13bc5b038262a0f310b7707317de38fa309598ad51" } ], "read_scope": "- [SAMHSA, Caring for Yourself](https://www.samhsa.gov/find-support/helping-someone/caring-for-yourself) — 24 April 2023; verified reuse of the author's own reading of the entire displayed official expanded text, direct opening InternalError; manageable support rather than treatment delivered by a relative.", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 13593, "end_utf16": 13901, "sha256_utf8": "6f024e6d0916a4581ae6b7e7f11116514340153be132d945869747e48582b0f1" }, "shared_entry_urls": [] } ], "retrieval_limits": [ "This local GEO representation applies only to the specified source article version and its SHA-256.", "Qualifications, sources and attributions remain in the full sections and byte-identical Markdown copy.", "No new source research was conducted in this GEO stage." ], "master_sha256": "703c23edc38c2943b192091cfb2c2d8623c3c9295856a32f0106f8d28bd1f601", "provenance": { "raw_reader_sha256": "703c23edc38c2943b192091cfb2c2d8623c3c9295856a32f0106f8d28bd1f601", "ru_master_sha256": "e391d7970c42563ca48f6a70d66797585886ae7297f59e02a37e6ba06e719f38", "reader_path": "outputs/uw-addictions-corpus-20261013/articles/DEP-06-N06/ARTICLE_EN.md", "review_pointer": "outputs/uw-addictions-corpus-20261013/articles/DEP-06-N06/INDEPENDENT_REVIEW.json", "review_sha256": "4ad24679f98142cef9038357e86c1d869191a0e3fb26001d8a6d63e6438ffaba", "clean_md_relative_filename": "GEO.en.md", "body_length_utf16": 14582, "source_segments": [ { "kind": "opening", "index": 0, "heading": null, "start_utf16": 0, "end_utf16": 34, "sha256_utf8_raw_slice": "52122319a67d500c73b3d1f9b33cee8cb0427a4ecb67cc86e4f0b1b282f65a56" }, { "kind": "h2_section", "index": 1, "heading": "Sleep, relief and questions about continuing treatment", "start_utf16": 34, "end_utf16": 1095, "sha256_utf8_raw_slice": "914c9904215b1d8c7c9eded31a211cf3494b7119c97993e5002e3f9bf6da3223" }, { "kind": "h2_section", "index": 2, "heading": "What is called a sleeping medicine?", "start_utf16": 1095, "end_utf16": 2258, "sha256_utf8_raw_slice": "e4aec019c3232d3a485ddfdc5642ce84615e0a09806e9c0e7b62c1860336e20e" }, { "kind": "h2_section", "index": 3, "heading": "Why an extended prescription deserves review", "start_utf16": 2258, "end_utf16": 3689, "sha256_utf8_raw_slice": "bd7ede154ed43347d9635507cde084403f21cc33ad1a292acb2321b359da0a8e" }, { "kind": "h2_section", "index": 4, "heading": "Adaptation, tolerance and addiction differ", "start_utf16": 3689, "end_utf16": 5133, "sha256_utf8_raw_slice": "6ff31a57cb78d8fed1c3ad75ed29ec43a39c9beb5f292e280ccc289f55e94f46" }, { "kind": "h2_section", "index": 5, "heading": "A poor night does not establish the cause", "start_utf16": 5133, "end_utf16": 6212, "sha256_utf8_raw_slice": "430876de1489dc35f2e70aa7443e679aa81771f85476325354d8a29a80f610b8" }, { "kind": "h2_section", "index": 6, "heading": "Caution matters after a night's sleep too", "start_utf16": 6212, "end_utf16": 7600, "sha256_utf8_raw_slice": "2ffe248264f0b4eb6725a33aa02e78607495e1a18b98ec949939619781e606be" }, { "kind": "h2_section", "index": 7, "heading": "Treating insomnia involves more than “pull yourself together”", "start_utf16": 7600, "end_utf16": 9100, "sha256_utf8_raw_slice": "1c4d7f834a955a907a2ee0e3b1b376e8157155adf0612e6c0880b29e2643783e" }, { "kind": "h2_section", "index": 8, "heading": "Support from relatives and five optional fields", "start_utf16": 9100, "end_utf16": 10651, "sha256_utf8_raw_slice": "c9f73155073bdd025ff8a6877e6a64f7e5cf39feb1194db838d235cf55d38304" }, { "kind": "h2_section", "index": 9, "heading": "Sources and limits", "start_utf16": 10651, "end_utf16": 13903, "sha256_utf8_raw_slice": "06486aad8d07cf405480f5b647df7cba735116407645878f34485bc552061503" }, { "kind": "h2_section", "index": 10, "heading": "Tags", "start_utf16": 13903, "end_utf16": 14109, "sha256_utf8_raw_slice": "cc13aacbc8009c34c9e0b5e21d735d2cddc64a5bd73c11b5488b8ef4f44696af" }, { "kind": "h2_section", "index": 11, "heading": "About the authors", "start_utf16": 14109, "end_utf16": 14582, "sha256_utf8_raw_slice": "d6b6d738ad7ec362dacb20b9eef0ecc9afe89201c6bdbfa109116cff85ded416" } ], "common_blocks_module_sha256": "6cf638661a819f960c39d08058bf6d0d0696e8b816f677d95b389f5f1d11e4d2" } }